NASDAQ:AARD
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$54.3M, and the diluted share count rose 391.1%.Summary generated from Aardvark Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−221.5%
Debt / equityn/a
Free cash flow−$54.3M
FCF marginn/a
Share count change+391.1%
Financials
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | n/a | 0 |
| Operating income | −23 | −63 |
| Net income | −21 | −58 |
| Free cash flow | −18 | −54 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 8-KDirector or officer change
Oct 8, 2026 - 4Insider transaction report
Sep 11, 2026 - 8-KResults of a shareholder vote
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - DEF 14AProxy statement
Jul 10, 2026 - 8-KDirector or officer change
Jun 12, 2026